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H e m o d y n a m i c a n d r e n a l effects of a t r i a l [5047 
n a t r i u r e t i c p e p t i d e ( α - h A N P ) i n n o r m a l m a n 
G Müeller-Esch, J Potratz, J M H e i m , Ρ Ball , S Klohs , J Alt , 
a n d P C Scriba, Depts. of Medicine and Biochem. 
Endocrinology, Medical Univ., Lübeck, and Dept. Medicine, 
Univ. München, FRG 
W e studied the h e m o d y n a m i c a n d renal actions of a - h A N P 
in 7 heal thy volunteers . 200 μ of α - h A N P were given as an 
intravenous bolus injection. M-mode-echocardiography w a s 
performed a n d s e r u m levels of A N P a n d c G M P as wel l as 
c G M P - , s o d i u m - a n d potassium excretion were determined. 
W i t h i n 2 m i n , a transient heart rate increase of 34% to­
gether w i t h a fall of m e a n arterial blood pressure of 11 % was 
observed. Stroke v o l u m e increased from 77.5 ± 1 5 . 1 to 
90.3 ± 10.2 m l a n d cardiac index from 2.44 ± 0.41 to 2.88 ± 
0.41 l / m 2 / m i n . Eject ion fraction rose from 62.9 ± 1.8 to 
73.5 ± 3.8% (p < 0.01). H e m o d y n a m i c changes were most 
pronounced f rom 10 to 15 m i n after injection a n d reached 
baseline values another 15 m i n later. S e r u m A N P rose 20fold; 
c G M P rose 8fold w i t h i n the first 15 m i n a n d normalized after 
1 hour. U r i n a r y c G M P excretion increased nearly 8fold, urine 
v o l u m e 9 fold, s o d i u m excretion 5 fold a n d potassium excretion 
doubled. T h e s e renal e f f e c t s — i n contrast to the hemody­
n a m i c c h a n g e s — s h o w e d a m a x i m u m w i t h i n the first 30 min, 
but were still present for at least 90 m i n later. N o severe side 
effects were observed. 
Conclusions: I m p r o v e d myocardia l performance together 
w i t h sustained diuresis a n d natriuresis m a y be of therapeutical 
benefit i n the acute treatment of congestive heart failure. The 
role of c G M P as a marker for A N P action is confirmed. 
